deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT01805557

Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. (FIL_VERAL12)

Sponsor: Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Conditions Diffuse Large B-cell Lymphoma Recurrent Diffuse Large B-cell Lymphoma Refractory
Interventions BR-DHAP R-DHAP
Updated 13 times since 2017 Last updated: Jun 6, 2022 Started: Feb 4, 2013 Primary completion: Mar 12, 2019 Completion: Nov 20, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Diffuse Large B-cell Lymphoma Recurrent and Diffuse Large B-cell Lymphoma Refractory, this trial is completed. The trial is conducted by Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte and has accumulated 13 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Mar 2018 · 14 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Dec 2019 · 9 months · monthly snapshot~Dec 2019 – ~Aug 2020 · 8 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2022 · 7 months · monthly snapshot~Jul 2022 – ~Jun 2023 · 11 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. Jun 2023 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  5. Jul 2022 — Jun 2023 [monthly]

    Completed PHASE2_PHASE3

▶ Show 8 earlier versions

  1. Dec 2021 — Jul 2022 [monthly]

    Completed PHASE2_PHASE3

  2. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2_PHASE3

    Status: Active Not Recruiting → Completed

  3. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  4. Dec 2019 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  5. Mar 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Unknown Status → Active Not Recruiting

  6. Jun 2018 — Mar 2019 [monthly]

    Unknown Status PHASE2_PHASE3

  7. Mar 2018 — Jun 2018 [monthly]

    Unknown Status PHASE2_PHASE3

    Status: Recruiting → Unknown Status

  8. Jan 2017 — Mar 2018 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
  • Fondazione Italiana Linfomi - ETS
  • Janssen Pharmaceutica
  • Janssen-Cilag Ltd.
Data source: Fondazione Italiana Linfomi - ETS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alessandria, Italy , Ancona, Italy , Aviano, Italy , Brescia, Italy , Cagliari, Italy , Gallarate, Italy , Genova, Italy , Meldola, Italy , Milan, Italy , Novara, Italy and 12 more locations